Impact on the composition of the faecal flora by a new p data on maintenance treatment of patients with ulcerat

Alimentary Pharmacology and Therapeutics

13, 1103-1108

DOI: 10.1046/j.1365-2036.1999.00560.x

Citation Report

#	Article	IF	Citations
1	Traditional and High Potency Probiotic Preparations for Oral Bacteriotherapy. BioDrugs, 1999, 12, 455-470.	2.2	23
2	Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?. Gastroenterology, 1999, 116, 1246-1249.	0.6	188
3	Bacteria and inflammatory bowel disease. Current Opinion in Infectious Diseases, 2000, 13, 503-509.	1.3	14
4	Medical therapy for ulcerative colitis. Current Opinion in Gastroenterology, 2000, 16, 324-328.	1.0	11
5	Probiotics in infective diarrhoea and inflammatory bowel diseases. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 489-493.	1.4	114
6	Specific Detection of Bifidobacterium Strains in a Pharmaceutical Probiotic Product and in Human Feces by Polymerase Chain Reaction. Systematic and Applied Microbiology, 2000, 23, 391-399.	1.2	46
7	Is Lactobacillus GG Helpful in Children With Crohnâ€™s Disease? Results of a Preliminary, Open-Label Study. Journal of Pediatric Gastroenterology and Nutrition, 2000, 31, 453-457.	0.9	348
8	The Role of Digestive Microflora and Probiotics in Inflammatory Bowel Disease. Microbial Ecology in Health and Disease, 2000, 12, 138-145.	3.8	2
9	Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology, 2000, 119, 305-309.	0.6	1,373
10	Probiotics in chronic pouchitis: Restoring luminal microbial balance. Gastroenterology, 2000, 119, 584-586.	0.6	52
11	Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology, 2001, 121, 580-591.	0.6	958
12	Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Research in Microbiology, 2001, 152, 735-741.	1.0	178
13	Recent Advances in Inflammatory Bowel Disease. Critical Reviews in Clinical Laboratory Sciences, 2001, 38, 33-108.	2.7	12
14	The Use of Probiotics in Gastrointestinal Disease. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 817-822.	1.8	100
15	Pre-, pro- and synbiotics. Current Opinion in Clinical Nutrition and Metabolic Care, 2001, 4, 571-579.	1.3	79
16	Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Alimentary Pharmacology and Therapeutics, 2001, 15, 1219-1225.	1.9	255
17	Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney International, 2001, 60, 1097-1105.	2.6	204
18	Intestinal transit of an orally administered streptomycin-rifampicin-resistant variant ofBifidobacterium longumSBT2928: its long-term survival and effect on the intestinal microflora and metabolism. Journal of Applied Microbiology, 2001, 90, 43-52.	1.4	57

#	Article	IF	Citations
19	Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes and Infection, 2001, 3, 1157-1166.	1.0	29
20	Bacteria as the cause of ulcerative colitis. Gut, 2001, 48, 132-135.	6.1	169
21	Fecal bacteriotherapy or probiotics for the treatment of intestinal diseases?. American Journal of Gastroenterology, 2001, 96, 2262-2263.	0.2	6
22	Helicobacter hepaticus-Induced Colitis in Interleukin-10-Deficient Mice: Cytokine Requirements for the Induction and Maintenance of Intestinal Inflammation. Infection and Immunity, 2001, 69, 4232-4241.	1.0	129
23	The Bacterial Flora in Inflammatory Bowel Disease: Current Insights in Pathogenesis and the Influence of Antibiotics and Probiotics. Scandinavian Journal of Gastroenterology, 2001, 36, 29-40.	0.6	178
24	Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. American Journal of Gastroenterology, 2002, 97, 2150-2152.	0.2	108
25	Effect of probiotic strains on interleukin 8 production by HT29/19A cells. American Journal of Gastroenterology, 2002, 97, 1182-1186.	0.2	135
26	Inflammatory Bowel Disease. New England Journal of Medicine, 2002, 347, 1982-1984.	13.9	12
27	New developments in the treatment of inflammatory bowel disease. Expert Opinion on Investigational Drugs, 2002, 11, 365-385.	1.9	14
28	Update in Medical Therapy of Ulcerative Colitis. Journal of Clinical Gastroenterology, 2002, 34, 397-407.	1.1	12
29	Nutritional Modulation of Gut Inflammation. , 2002, 7, 41-65.		4
30	Probiotics in the third millennium. Digestive and Liver Disease, 2002, 34, S2-S7.	0.4	80
31	Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Digestive and Liver Disease, 2002, 34, S48-S53.	0.4	54
32	Probiotics â€" Role in inflammatory bowel disease. Digestive and Liver Disease, 2002, 34, S58-S62.	0.4	46
33	Use of lactobacillus-GG in paediatric Crohn's disease. Digestive and Liver Disease, 2002, 34, S63-S65.	0.4	51
34	The place of probiotics in human intestinal infections. International Journal of Antimicrobial Agents, 2002, 20, 313-319.	1.1	87
35	Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. Journal of Gastroenterology, 2002, 37, 67-72.	2.3	178
36	Intestinal microflora as a therapeutic target in inflammatory bowel disease. Journal of Gastroenterology, 2002, 37, 73-77.	2.3	24

#	Article	IF	Citations
37	Medical therapy for ulcerative colitis. Gastroenterology Clinics of North America, 2002, 31, 147-166.	1.0	45
38	Ulcerative colitis. Lancet, The, 2002, 359, 331-340.	6.3	273
39	Selection of probiotics and prebiotics for synbiotics and confirmation of their in vivo effectiveness. Food Research International, 2002, 35, 125-131.	2.9	140
40	Probiotics in health and disease in the pediatric patient. Pediatric Clinics of North America, 2002, 49, 127-141.	0.9	24
42	Microbial factors in inflammatory bowel disease. Gastroenterology Clinics of North America, 2002, 31, 41-62.	1.0	122
43	Effects of Lactobacillus gasseri SBT2055 on Dextran Sulfate Sodium-Induced Ulcerative Colitis Model in Rats. Bioscience and Microflora, 2002, 21, 179-183.	0.5	6
44	Gut bacteria and health foodsâ€"the European perspective. International Journal of Food Microbiology, 2002, 78, 99-117.	2.1	236
45	Intestinal microbial patterns of the common marmoset and rhesus macaque. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2002, 133, 379-388.	0.8	13
46	Probiotics: potential pharmaceutical applications. European Journal of Pharmaceutical Sciences, 2002, 15, 1-9.	1.9	271
47	Pouchitis in children: Therapeutic options. Current Treatment Options in Gastroenterology, 2002, 5, 389-397.	0.3	5
49	Maintenance of remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2002, 16, 21-24.	1.9	26
50	Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Alimentary Pharmacology and Therapeutics, 2002, 16, 1461-1467.	1.9	292
51	Lactose - a potential prebiotic. Alimentary Pharmacology and Therapeutics, 2002, 16, 1591-1602.	1.9	79
52	Probiotic therapy for pouchitis and its endoscopic findings. Digestive Endoscopy, 2002, 14, 47-52.	1.3	4
53	Lactobacillus plantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice. Inflammatory Bowel Diseases, 2002, 8, 71-80.	0.9	325
54	Variable Response to Probiotics in Two Models of Experimental Colitis in Rats. Inflammatory Bowel Diseases, 2002, 8, 399-406.	0.9	115
55	Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission. Digestive Diseases and Sciences, 2002, 47, 2811-2822.	1.1	21
56	Diagnosis and treatment of pouchitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 75-87.	1.0	37

#	Article	IF	Citations
57	Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003, 37, 343-350.	3.6	800
58	Future therapies for inflammatory bowel disease. Current Gastroenterology Reports, 2003, 5, 518-523.	1.1	11
59	Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. Journal of Gastroenterology, 2003, 38, 134-141.	2.3	82
60	Using probiotics and prebiotics to improve gut health. Drug Discovery Today, 2003, 8, 692-700.	3.2	315
61	Quantitative Detection of Probiotic Bifidobacterium Strains in Bacterial Mixtures by Using Real-time PCR. Systematic and Applied Microbiology, 2003, 26, 269-276.	1.2	40
62	PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. International Journal of Food Microbiology, 2003, 81, 203-209.	2.1	85
63	Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 45-56.	1.9	163
64	The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Alimentary Pharmacology and Therapeutics, 2003, 18, 495-505.	1.9	80
65	Probiotics for the treatment of postoperative complications following intestinal surgery. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 821-831.	1.0	41
66	Genetically engineered probiotics. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 861-876.	1.0	93
67	Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124, 1202-1209.	0.6	1,048
68	Prevention is the best defense: probiotic prophylaxis of pouchitis. Gastroenterology, 2003, 124, 1535-1538.	0.6	31
69	Probiotics can treat hepatic encephalopathy. Medical Hypotheses, 2003, 61, 307-313.	0.8	82
70	Novel therapies in the treatment of ulcerative colitis. Expert Opinion on Investigational Drugs, 2003, 12, 483-490.	1.9	4
71	Use of Mouse Models To Evaluate the Persistence, Safety, and Immune Modulation Capacities of Lactic Acid Bacteria. Vaccine Journal, 2003, 10, 696-701.	3.2	113
72	Probiotics and Inflammatory Bowel Disease. BioDrugs, 2003, 17, 179-186.	2.2	9
73	Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut, 2003, 52, 370-376.	6.1	199
74	Disease-Dependent Adhesion of Lactic Acid Bacteria to the Human Intestinal Mucosa. Vaccine Journal, 2003, 10, 643-646.	3.2	37

#	Article	IF	Citations
75	The Role of Probiotics in Gastrointestinal Disease. Nutrition in Clinical Practice, 2003, 18, 507-516.	1.1	20
76	Tropomyosin Expression in The Ileal Pouch: A Relationship With The Development of Pouchitis in Ulcerative Colitis. American Journal of Gastroenterology, 2003, 98, 2719-2726.	0.2	37
77	Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut, 2003, 52, 988-997.	6.1	522
78	Standard Treatment of Ulcerative Colitis. Digestive Diseases, 2003, 21, 157-167.	0.8	37
79	Modern Therapy for Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 2003, 38, 30-33.	0.6	7
80	Gut changes attributed to ageing: effects on intestinal microflora. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 49-54.	1.3	94
81	Nutritional and metabolic issues in inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 569-576.	1.3	13
82	Use of Probiotics in the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2003, 36, 111-119.	1.1	94
83	Treatment of Pouchitis. Topics in Clinical Nutrition, 2003, 18, 162-169.	0.2	0
84	Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases. Digestive Diseases, 2003, 21, 105-128.	0.8	48
85	Bioactive natural compounds for the treatment of gastrointestinal disorders. Clinical Science, 2003, 104, 547-556.	1.8	72
86	The Prebiotic Characteristics of Fructooligosaccharides Are Necessary for Reduction of TNBS-Induced Colitis in Rats. Journal of Nutrition, 2003, 133, 21-27.	1.3	164
87	Probiotics and Inflammatory Bowel Disease. Journal of the Royal Society of Medicine, 2003, 96, 167-171.	1.1	60
89	Failure to Improve Parameters of Lactose Maldigestion using the Multiprobiotic Product VSL3 in Lactose Maldigesters: A Pilot Study. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 83-86.	1.8	17
90	Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. American Journal of Physiology - Renal Physiology, 2004, 286, G613-G626.	1.6	348
91	Assessing the effectiveness of probiotics, prebiotics and synbiotics in preventing diseases. , 2004, , 726-752.		0
92	Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004, 53, 108-114.	6.1	783
93	Bacteriophage Defense Systems and Strategies for Lactic Acid Bacteria. Advances in Applied Microbiology, 2004, 56, 331-378.	1.3	42

#	Article	IF	Citations
94	Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut, 2004, 53, 620-622.	6.1	83
95	Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut, 2004, 53, 694-700.	6.1	170
96	Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut, 2004, 53, 685-693.	6.1	1,073
97	Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53, 1617-1623.	6.1	1,012
98	Preventive Effects of Escherichia coli Strain Nissle 1917 on Acute and Chronic Intestinal Inflammation in Two Different Murine Models of Colitis. Vaccine Journal, 2004, 11, 372-378.	3.2	103
99	Das prÃnatale/frÃ¼hkindliche Immunsystem und Allergie â€“ Ergebnisse humaner und tierexperimenteller Studien / Prenatal and early postnatal immune system and allergy â€“ outcomes of human and animal studies. Laboratoriums Medizin, 2004, 28, 273-278.	0.1	1
100	Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chinese Journal of Digestive Diseases, 2004, 5, 169-174.	1.1	96
101	Improvement of human faecal flora-associated mouse model for evaluation of the functional foods. Journal of Applied Microbiology, 2004, 96, 656-663.	1.4	37
102	Probiotics and the Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 286-299.	0.9	155
103	Patterns of Complementary and Alternative Medicine Use in a Population of Pediatric Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 599-605.	0.9	32
105	Protective Effect of Lactulose on Dextran Sulfate Sodium-Induced Colonic Inflammation in Rats. Digestive Diseases and Sciences, 2004, 49, 1466-1472.	1.1	77
106	Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterology, 2004, 4, 5.	0.8	277
107	Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiology Reviews, 2004, 28, 405-440.	3.9	957
108	DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology, 2004, 126, 1358-1373.	0.6	294
109	Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology, 2004, 126, 1620-1633.	0.6	952
110	Current therapy of ulcerative colitis in children. Expert Opinion on Pharmacotherapy, 2004, 5, 37-53.	0.9	10
111	Potential and Opportunities for Use of Recombinant Lactic Acid Bacteria in Human Health. Advances in Applied Microbiology, 2004, 56, 1-64.	1.3	67
112	In vitro alterations of intestinal bacterial microbiota in fecal samples during storage. Diagnostic Microbiology and Infectious Disease, 2004, 50, 237-245.	0.8	105

#	Article	IF	Citations
113	Beclomethasone Dipropionate Plus VSL#3 for the Treatment of Mild to Moderate Diverticular Colitis: An Open, Pilot Study. Journal of Clinical Gastroenterology, 2005, 39, 644-645.	1.1	16
114	The VSL# 3 Probiotic Mixture Modifies Microflora but Does Not Heal Chronic Dextran-Sodium Sulfateâ€"Induced Colitis or Reinforce the Mucus Barrier in Mice. Journal of Nutrition, 2005, 135, 2753-2761.	1.3	96
115	Update in Medical Therapy of Ulcerative Colitis. Journal of Clinical Gastroenterology, 2005, 39, 557-569.	1.1	27
116	Probiotics Used in Human Studies. Journal of Clinical Gastroenterology, 2005, 39, 469-484.	1.1	55
117	Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases. Journal of Clinical Gastroenterology, 2005, 39, 540-543.	1.1	406
118	Nonpathogenic Escherichia coli Strain Nissle1917 Prevents Murine Acute and Chronic Colitis. Inflammatory Bowel Diseases, 2005, 11, 455-463.	0.9	62
119	Molecular Characterization of Rectal Mucosa-Associated Bacterial Flora in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2005, 11, 481-487.	0.9	222
120	Preventative Effects of Lactulose in the Trinitrobenzenesulphonic Acid Model of Rat Colitis. Inflammatory Bowel Diseases, 2005, 11, 265-271.	0.9	90
121	Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin-1Î², Interleukin-8, and Interferon-Î³ Gene Expression. Inflammatory Bowel Diseases, 2005, 11, 447-454.	0.9	61
122	Aetiology of inflammatory bowel disease (IBD): Role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clinical Nutrition, 2005, 24, 339-352.	2.3	105
123	Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. International Journal of Food Microbiology, 2005, 103, 143-155.	2.1	93
125	Chronisch entzÃ¼ndliche Darmerkrankungen. , 2005, , 248-287.		0
126	Mucosal bacteria in ulcerative colitis. British Journal of Nutrition, 2005, 93, S67-S72.	1.2	57
127	Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 2005, 54, 242-249.	6.1	620
128	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. American Journal of Gastroenterology, 2005, 100, 1539-1546.	0.2	659
129	Bioecologic Control of the Gastrointestinal Tract: The Role of Flora and Supplemented Probiotics and Synbiotics. Gastroenterology Clinics of North America, 2005, 34, 413-436.	1.0	64
130	The Role of Enteric Microflora in Inflammatory Bowel Disease: Human and Animal Studies with Probiotics and Prebiotics. Gastroenterology Clinics of North America, 2005, 34, 465-482.	1.0	51
131	VSL#3: An Analysis of Basic and Clinical Contributions in Probiotic Therapeutics. Gastroenterology Clinics of North America, 2005, 34, 499-513.	1.0	30

#	Article	IF	Citations
132	Probiotics and barrier function in colitis. Gut, 2005, 54, 898-900.	6.1	21
133	Probiotics and inflammatory bowel disease: a natural fit?. Expert Review of Clinical Immunology, 2005, 1, 489-492.	1.3	0
134	Use of Probiotics in Humans: An Analysis of the Literature. Gastroenterology Clinics of North America, 2005, 34, 547-570.	1.0	42
135	New therapeutic strategy for combating the increasing burden of allergic disease: Probioticsâ€"A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy and Clinical Immunology, 2005, 116, 31-37.	1.5	122
136	Probiotics: wanted dead or alive. Digestive and Liver Disease, 2005, 37, 3-6.	0.4	30
137	Lactobacillus casei DN-114 001 Inhibits the Ability of Adherent-Invasive Escherichia coli Isolated from Crohn's Disease Patients To Adhere to and To Invade Intestinal Epithelial Cells. Applied and Environmental Microbiology, 2005, 71, 2880-2887.	1.4	85
138	Current Therapy of Inflammatory Bowel Disease in Children. Paediatric Drugs, 2006, 8, 279-302.	1.3	95
139	A traditional Japanese medicine mitigates TNBS-induced colitis in rats. Scandinavian Journal of Gastroenterology, 2006, 41, 1183-1189.	0.6	12
140	Probiotics in Inflammatory Bowel Disease. Seminars in Colon and Rectal Surgery, 2006, 17, 55-60.	0.2	1
141	VSL#3 Probiotic Mixture. Drugs, 2006, 66, 1371-1387.	4.9	97
142	Gastrointestinal Microflora: Probiotics. Advances in Applied Microbiology, 2006, 59, 187-219.	1.3	37
143	Intestinal survival and persistence of probiotic Lactobacillus and Bifidobacterium strains administered in triple-strain yoghurt. International Dairy Journal, 2006, 16, 1174-1180.	1.5	54
144	Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World Journal of Gastroenterology, 2006, 12, 5987.	1.4	47
145	Antibiotics and probiotics in treatment of inflammatory bowel disease. World Journal of Gastroenterology, 2006, 12, 3306.	1.4	122
146	Probiotics and the gastrointestinal tract: Where are we in 2005. World Journal of Gastroenterology, 2006, 12, 853.	1.4	38
147	Probiotics and prebiotics in chronic inflammatory bowel diseases. World Journal of Gastroenterology, 2006, 12, 5941.	1.4	133
150	Clinical Efficacy of Probiotics. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 550-557.	0.9	93
151	Probiotics in the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2006, 40, 260-263.	1.1	78

#	Article	IF	Citations
152	Recommendations for Probiotic Use. Journal of Clinical Gastroenterology, 2006, 40, 275-278.	1.1	56
153	Mesalazine and/or Lactobacillus casei in Preventing Recurrence of Symptomatic Uncomplicated Diverticular Disease of the Colon. Journal of Clinical Gastroenterology, 2006, 40, 312-316.	1.1	112
154	Health Claims Associated with Probiotics. , 0, , 138-166.		2
155	Synbiotic Therapy: A Promising New Adjunctive Therapy for Ulcerative Colitis. Nutrition Reviews, 2006, 64, 132-138.	2.6	15
156	Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases, 2006, 12, S3-S9.	0.9	756
157	Probiotics: Do They Help to Control Intestinal Inflammation?. Annals of the New York Academy of Sciences, 2006, 1072, 339-350.	1.8	29
158	Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. International Journal of Colorectal Disease, 2006, 21, 737-746.	1.0	121
159	Partially hydrolyzed guar gum down-regulates colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Journal of Nutritional Biochemistry, 2006, 17, 402-409.	1.9	56
160	The role of antibiotic and probiotic therapies in current and future management of inflammatory Bowel disease. Current Gastroenterology Reports, 2006, 8, 486-498.	1.1	37
161	Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition, 2006, 22, 76-81.	1.1	62
162	Probiotics for maintenance of remission in Crohn's disease. The Cochrane Library, 2006, , CD004826.	1.5	136
163	Recent advances in the etiology and treatment of inflammatory bowel disease. Expert Review of Clinical Immunology, 2006, 2, 245-256.	1.3	0
164	Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut, 2006, 55, 191-196.	6.1	202
165	Optimizing management of distal ulcerative colitis. Scandinavian Journal of Gastroenterology, 2006, 41, 511-523.	0.6	4
166	Probiotics in Primary Care Pediatrics. Clinical Pediatrics, 2006, 45, 405-410.	0.4	43
167	Probiotics in the Management of Inflammatory Bowel Diseases?. American Journal of Gastroenterology, 2007, 102, S22-S28.	0.2	4
168	New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opinion on Pharmacotherapy, 2007, 8, 299-307.	0.9	53
169	Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria. Scandinavian Journal of Gastroenterology, 2007, 42, 592-601.	0.6	19

#	Article	IF	Citations
170	Probiotics, prebiotics, and inflammatory bowel disease. , 2007, , 90-116.		1
171	Lactobacillus Acidophilus Strain L-92 Regulates the Production of Th1 Cytokine as well as Th2 Cytokines. Allergology International, 2007, 56, 293-301.	1.4	99
172	Identification of Commensal Bacterial Strains That Modulate Yersinia enterocolitica and Dextran Sodium Sulfate-Induced Inflammatory Responses: Implications for the Development of Probiotics. Infection and Immunity, 2007, 75, 3490-3497.	1.0	50
173	Nutritional value of yoghurt. , 2007, , 646-684.		3
174	Probiotic Effects on Inflammatory Bowel Disease1,. Journal of Nutrition, 2007, 137, 819S-824S.	1.3	137
175	Cross-Talk between Probiotic Bacteria and the Host Immune System1,. Journal of Nutrition, 2007, 137, 781S-790S.	1.3	276
176	A comparative study of the preventative effects exerted by two probiotics,Lactobacillus reuteriandLactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. British Journal of Nutrition, 2007, 97, 96-103.	1.2	142
177	Prebiotics, Probiotics, and Dietary Fiber in Gastrointestinal Disease. Gastroenterology Clinics of North America, 2007, 36, 47-63.	1.0	63
178	Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. The Cochrane Library, 2007, , CD005165.	1.5	65
179	Treatment options for children with inflammatory bowel disease (IBD) have improved, but still don??t get full marks. Drugs and Therapy Perspectives, 2007, 23, 9-12.	0.3	0
180	Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases1. BioDrugs, 2007, 21, 61-63.	2.2	29
183	Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proceedings of the Nutrition Society, 2007, 66, 307-315.	0.4	172
184	Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 1277-1283.	0.9	218
185	Pathogenesis of hepatic encephalopathy: the tumour necrosis factor-? theory. European Journal of Clinical Investigation, 2007, 37, 291-304.	1.7	73
186	Microbial biofilms in the human gastrointestinal tract. Journal of Applied Microbiology, 2007, 102, 1187-1196.	1.4	301
187	A comparative study of the preventative effects exerted by three probiotics,Bifidobacterium lactis,Lactobacillus caseiandLactobacillus acidophilus, in the TNBS model of rat colitis. Journal of Applied Microbiology, 2007, 103, 836-844.	1.4	111
188	Review article: probiotics in gastrointestinal and liver diseases. Alimentary Pharmacology and Therapeutics, 2007, 26, 133-148.	1.9	66
189	Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. International Journal of Food Microbiology, 2007, 114, 267-274.	2.1	108

#	Article	IF	Citations
190	Inflammatory bowel disease: Current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. International Journal of Food Microbiology, 2007, 115, 1-11.	2.1	141
191	Bioecological control of inflammatory bowel disease. Clinical Nutrition, 2007, 26, 169-181.	2.3	25
192	Probiotic Supplementation with Lactobacillus casei (Actimel) Induces a Th1 Response in an Animal Model of Antiphospholipid Syndrome. Annals of the New York Academy of Sciences, 2007, 1110, 661-669.	1.8	11
193	Probiotics and prebiotics â€" renaissance of a therapeutic principle. Open Medicine (Poland), 2007, 2, 237-270.	0.6	37
194	The Role of Probiotics in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2007, 52, 607-611.	1.1	35
195	Bifidobacterium longum with Fructo-Oligosaccharide (FOS) Treatment in Minimal Hepatic Encephalopathy: A Randomized, Double-Blind, Placebo-Controlled Study. Digestive Diseases and Sciences, 2007, 52, 3259-3265.	1.1	162
196	High-Dose Probiotics for the Treatment of Active Pouchitis. Diseases of the Colon and Rectum, 2007, 50, 2075-2084.	0.7	179
197	Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease, 2007, 22, 1103-1108.	1.0	81
198	Therapeutic Potential of Two Probiotics in Inflammatory Bowel Disease as observed in the Trinitrobenzene Sulfonic Acid Model of Colitis. Diseases of the Colon and Rectum, 2008, 51, 1828-1836.	0.7	28
199	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. Molecular Nutrition and Food Research, 2008, 52, 906-912.	1.5	35
200	Probiotics: Benefits in Human Health and Bacterial Disease Management. , 0, , 275-295.		0
201	Gut instincts: Explorations in intestinal physiology and drug delivery. International Journal of Pharmaceutics, 2008, 364, 213-226.	2.6	394
202	Probiotics and oral healthcare. Periodontology 2000, 2008, 48, 111-147.	6.3	112
203	Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 815-829.	1.9	15
204	Probiotics and prebiotics in inflammatory bowel disease: microflora â€˜on the scopeâ€™. British Journal of Clinical Pharmacology, 2008, 65, 453-467.	1.1	122
205	Genes, bacteria and inflammatory bowel disease. Colorectal Disease, 2001, 3, 2-6.	0.7	0
206	The potential influence of fruit polyphenols on colonic microflora and human gut health. International Journal of Food Microbiology, 2008, 124, 295-298.	2.1	296
207	A Review of Complementary and Alternative Approaches to Immunomodulation. Nutrition in Clinical Practice, 2008, 23, 49-62.	1.1	86

#	Article	IF	Citations
208	Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. Journal of Hepatology, 2008, 49, 821-830.	1.8	364
209	Integrative medicine in gastrointestinal disease: evaluating the evidence. Expert Review of Gastroenterology and Hepatology, 2008, 2, 261-280.	1.4	9
210	Rationale for probiotic treatment strategies in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2008, 2, 337-355.	1.4	20
211	Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1131-R1137.	0.9	61
212	Clinical Indications for Probiotics: An Overview. Clinical Infectious Diseases, 2008, 46, S96-S100.	2.9	178
213	Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opinion on Therapeutic Targets, 2008, 12, 301-312.	1.5	18
214	Pathophysiology of Inflammatory Bowel Diseases. , 2008, , 341-373.		2
215	Role of the intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 2008, 14, 401.	1.4	238
216	Probiotics and Prebiotics as Functional Ingredients in Inflammatory Bowel Disease. Nutrition Today, 2008, 43, 235-242.	0.6	3
217	Probiotics in the Treatment of Human Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2008, 42, S97-S103.	1.1	29
218	Recommendations for Probiotic Useâ€”2008. Journal of Clinical Gastroenterology, 2008, 42, S104-S108.	1.1	120
219	Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions. Current Opinion in Pulmonary Medicine, 2008, 14, 168-175.	1.2	29
220	Probiotics: sorting the evidence from the myths. Medical Journal of Australia, 2008, 188, 304-308.	0.8	59
221	Probiotics in GI Diseases. Frontiers of Gastrointestinal Research, 2009, , 126-134.	0.1	1
222	Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. American Journal of Physiology - Renal Physiology, 2009, 296, G1140-G1149.	1.6	392
223	The Effects of Heat-Killed Wild-Type <i>Lactobacillus casei </i>Shirota on Allergic Immune Responses in an Allergy Mouse Model. International Archives of Allergy and Immunology, 2009, 148, 297-304.	0.9	37
224	A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition, 2009, 25, 520-525.	1.1	192
225	Mechanisms of action of probiotics: Recent advances. Inflammatory Bowel Diseases, 2009, 15, 300-310.	0.9	448

#	Article	IF	Citations
226	Therapeutic strategies for the management of ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 935-950.	0.9	65
227	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflammatory Bowel Diseases, 2009, 15, 760-768.	0.9	119
228	Probiotics in pediatric inflammatory bowel diseases. Current Gastroenterology Reports, 2009, 11, 238-247.	1.1	4
229	New nutritional approach to inflammatory bowel disease: the nutraceuticals. Mediterranean Journal of Nutrition and Metabolism, 2009, 1, 145-148.	0.2	0
230	Probiotics and health: a review of the evidence. Nutrition Bulletin, 2009, 34, 340-373.	0.8	73
231	Effect of Probiotics on Intestinal Barrier Function. Annals of the New York Academy of Sciences, 2009, 1165, 183-189.	1.8	124
232	Emerging drugs for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs, 2009, 14, 505-521.	1.0	24
233	Vieillissement du tube digestif et modifications de la flore intestinale liÃ©es Ã lâ€™Ã¢ge. , 2009, , 89-93.		0
234	Chapter 1 Understanding the Mechanisms by Which Probiotics Inhibit Gastrointestinal Pathogens. Advances in Food and Nutrition Research, 2009, 56, 1-15.	1.5	129
235	AttualitÃ e controversie nella terapia delle malattie infiammatorie croniche intestinali. Italian Journal of Medicine, 2009, 3, 179-186.	0.2	0
236	Probiotics Reduce the Inflammatory Response Induced by a High-Fat Diet in the Liver of Young Rats. Journal of Nutrition, 2009, 139, 905-911.	1.3	201
237	Intestinal bacteria and inflammatory bowel disease. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 25-54.	2.7	82
238	Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis. American Journal of Gastroenterology, 2009, 104, 437-443.	0.2	443
239	Clinical Evidence for Immunomodulatory Effects of Probiotic Bacteria. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 126-141.	0.9	57
240	The Impact of Probiotic on Gut Health. Current Drug Metabolism, 2009, 10, 68-78.	0.7	190
241	Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 260-269.	1.1	41
243	Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complementary and Alternative Medicine, 2010, 10, 13.	3.7	165
244	Clinical trial: the effects of a probiotic mixture on nonâ€steroidal antiâ€inflammatory drug enteropathy â€“ a randomized, doubleâ€blind, crossâ€over, placeboâ€controlled study. Alimentary Pharmacology and Therapeutics, 2010, 32, 209-214.	1.9	73

#	Article	IF	Citations
245	Probiotic Treatment of Colitis in Animal Models and People. , 2010, , 571-587.		0
246	Decrease in Frequency of Liquid Stool in Enterally Fed Critically Ill Patients Given the Multispecies Probiotic VSL#3: A Pilot Trial. American Journal of Critical Care, 2010, 19, e1-e11.	0.8	43
247	Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Probiotics in Chronic Inflammatory Bowel Disease and the Functional Disorder Irritable Bowel Syndrome. Journal of Nutrition, 2010, 140, 690S-697S.	1.3	79
248	Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Gastroenterology, 2010, 105, 2218-2227.	0.2	390
249	How Bacteria-Induced Apoptosis of Intestinal Epithelial Cells Contributes to Mucosal Inflammation. International Journal of Inflammation, 2010, 2010, 1-9.	0.9	30
251	Molecular crosstalk of probiotic bacteria with the intestinal immune system: Clinical relevance in the context of inflammatory bowel disease. International Journal of Medical Microbiology, 2010, 300, 63-73.	1.5	92
252	Importance of food in probiotic efficacy. Food Research International, 2010, 43, 1-7.	2.9	458
253	Effect of kale and papaya supplementation in colitis induced by trinitrobenzenesulfonic acid in the rat. European E-journal of Clinical Nutrition and Metabolism, 2010, 5, e111-e116.	0.4	18
254	Dietary Components and Immune Function. , 2010, , .		13
255	Probiotics and Prebiotics. , 2010, , 205-227.		14
256	Probiotics for maintenance of remission in ulcerative colitis. The Cochrane Library, 2011, , CD007443.	1.5	80
257	Epithelial Barriers in Intestinal Inflammation. Antioxidants and Redox Signaling, 2011, 15, 1255-1270.	2.5	145
258	Nutritional Modulation of the Inflammatory Bowel Response. Digestion, 2011, 84, 89-101.	1.2	28
259	Probiotic Bacteria and Enteric Infections. , 2011, , .		4
260	Potential Application of Probiotics in the Prevention and Treatment of Inflammatory Bowel Diseases. Ulcers, 2011, 2011, 1-13.	1.0	18
261	Identification and Characterisation of an Iron-Responsive Candidate Probiotic. PLoS ONE, 2011, 6, e26507.	1.1	21
262	Effect of a multi-species synbiotic formulation on fecal bacterial microbiota of healthy cats and dogs as evaluated by pyrosequencing. FEMS Microbiology Ecology, 2011, 78, 542-554.	1.3	116
263	Rectal Administration of Lactobacillus casei DG Modifies Flora Composition and Toll-Like Receptor Expression in Colonic Mucosa of Patients with Mild Ulcerative Colitis. Digestive Diseases and Sciences, 2011, 56, 1178-1187.	1.1	81

#	Article	IF	Citations
264	Health benefits of probiotics: are mixtures more effective than single strains?. European Journal of Nutrition, 2011, 50, 1-17.	1.8	360
265	Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 362-381.	0.9	466
266	Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. American Journal of Physiology - Renal Physiology, 2011, 300, G1115-G1123.	1.6	47
267	Intestinal microbiota in inflammatory bowel disease: Friend of foe?. World Journal of Gastroenterology, 2011, 17, 557.	1.4	253
268	Functional foods for the gut: probiotics, prebiotics and synbiotics. , 2011, , 449-470.		5
269	Key questions to guide a better understanding of hostâ€“commensal microbiota interactions in intestinal inflammation. Mucosal Immunology, 2011, 4, 127-132.	2.7	69
270	The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential. Biomolecules and Therapeutics, 2011, 19, 155-173.	1.1	5
271	Bacterial proteases in IBD and IBS. Gut, 2012, 61, 1610-1618.	6.1	97
273	Does VSL#3 Really Improve Symptoms in Children With IBS?. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 109-109.	0.9	2
274	Clinical review: Probiotics in critical care. Critical Care, 2012, 16, 237.	2.5	26
275	Probiotic Bacteria in the Prevention and the Treatment of Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2012, 41, 821-842.	1.0	21
276	Dietary Intervention for Improving Human Health: Chronic Disorders. , 2012, , 181-199.		0
277	Probiotics in the Management of Inflammatory Bowel Disease. Drugs, 2012, 72, 803-823.	4.9	187
278	Bacterial Flora as a Cause or Treatment of Chronic Diarrhea. Gastroenterology Clinics of North America, 2012, 41, 581-602.	1.0	17
279	Probiotics: defenders of gastrointestinal habitats. Gastroenterology Insights, 2012, 4, 22.	0.7	2
280	Immune Disorders and Its Correlation with Gut Microbiome. Immune Network, 2012, 12, 129.	1.6	45
281	Probiotics Applications in Autoimmune Diseases. , 0, , .		6
284	Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review. Journal of Complementary and Integrative Medicine, 2013, 10, .	0.4	10

#	Article	IF	Citations
285	NSAID enteropathy: could probiotics prevent it?. Journal of Gastroenterology, 2013, 48, 689-697.	2.3	27
286	Comparative in vitro inhibition of urinary tract pathogens by single- and multi-strain probiotics. European Journal of Nutrition, 2013, 52, 1669-1677.	1.8	31
287	Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora. Clinical Journal of Gastroenterology, 2013, 6, 345-351.	0.4	2
288	Effects of the Modulation of Microbiota on the Gastrointestinal Immune System and Bowel Function. Journal of Agricultural and Food Chemistry, 2013, 61, 9977-9983.	2.4	40
289	Anti-Inflammatory Properties of Genetically Modified Lactic Acid Bacteria. , 2013, , 581-600.		0
290	Republished: Bacterial proteases in IBD and IBS. Postgraduate Medical Journal, 2013, 89, 25-33.	0.9	8
292	Probiotics and clinical effects: is the number what counts?. Journal of Chemotherapy, 2013, 25, 193-212.	0.7	58
293	Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study). Pakistan Journal of Medical Sciences, 2013, 29, 490-4.	0.3	18
295	Development of Microencapsulation Delivery System for Long-Term Preservation of Probiotics as Biotherapeutics Agent. BioMed Research International, 2013, 2013, 1-21.	0.9	114
296	Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. BioMed Research International, 2013, 2013, 1-9.	0.9	156
297	<scp>VSL</scp>#3^{Â®} probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver International, 2013, 33, 1470-1477.	1.9	44
298	Probiotics in cirrhosis: do we expect too much?. Liver International, 2013, 33, 1451-1453.	1.9	4
299	VSL#3 probiotics provide protection against acute intestinal ischaemia/reperfusion injury. Beneficial Microbes, 2013, 4, 357-365.	1.0	16
300	Lactobacillus Bacteremia Associated With Probiotic Use in a Pediatric Patient With Ulcerative Colitis. Journal of Clinical Gastroenterology, 2013, 47, 437-439.	1.1	122
301	Actual concept of "probiotics": Is it more functional to science or business?. World Journal of Gastroenterology, 2013, 19, 1527.	1.4	51
302	Gastrointestinal microorganisms in cats and dogs: a brief review. Archivos De Medicina Veterinaria, 2013, 45, 111-124.	0.2	12
303	Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome. PLoS ONE, 2013, 8, e63893.	1.1	89
304	Effects of probiotics and prebiotics in ulcerative colitis. Bratislava Medical Journal, 2013, 114, 540-543.	0.4	7

#	Article	IF	Citations
305	Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 11505.	1.4	147
306	Current and emerging maintenance therapies for ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2014, 8, 359-368.	1.4	6
307	Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?. Proceedings of the Nutrition Society, 2014, 73, 490-497.	0.4	34
308	Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open, 2014, 4, e005047-e005047.	0.8	160
309	Small molecule immunomodulins from cultures of the human microbiome member Lactobacillus plantarum. Journal of Antibiotics, 2014, 67, 85-88.	1.0	26
310	Role of the intestinal microbiota and fecal transplantation in inflammatory bowel diseases. Journal of Digestive Diseases, 2014, 15, 641-646.	0.7	27
311	Gut Microbiota and Inflammatory Bowel Disease: The Role of Antibiotics in Disease Management. Postgraduate Medicine, 2014, 126, 7-19.	0.9	203
312	Future directions in inflammatory bowel disease management. Journal of Crohn's and Colitis, 2014, 8, 726-734.	0.6	90
313	Probiotic functional foods: Survival of probiotics during processing and storage. Journal of Functional Foods, 2014, 9, 225-241.	1.6	791
315	Correction of Microbiota Disturbances or Antagonism Against Specific Pathogens in IBD. , 2014, , 238-259.		0
316	Kinetics of Batch Fermentation in the Cultivation of a Probiotic Strain Lactobacillus Delbrueckii Ssp. Bulgaricus B1. Acta Universitatis Cibiniensis Series E: Food Technology, 2015, 19, 61-72.	0.6	2
317	Evaluation of viability Bifidobacterium animalis subsp. lactis LKM512 in dogs. Beneficial Microbes, 2015, 6, 791-797.	1.0	1
318	Probiotics in the Management of Ulcerative Colitis. Journal of Clinical Gastroenterology, 2015, 49, S50-S55.	1.1	47
319	Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases. International Journal of Molecular Sciences, 2015, 16, 20841-20858.	1.8	90
320	The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials. BioMed Research International, 2015, 2015, 1-15.	0.9	255
321	Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 215.	0.2	62
322	Probiotics: The Scientific Evidence in the Context of Inflammatory Bowel Disease. Critical Reviews in Food Science and Nutrition, 2017, 57, 00-00.	5.4	35
323	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. , 2015, 149, 191-212.		139

#	Article	IF	Citations
324	New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics. Clinical Infectious Diseases, 2015, 60, S108-S121.	2.9	194
326	Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 781-795.	1.4	48
327	<scp>VSL</scp>#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachlorideâ€induced cirrhosis. Liver International, 2015, 35, 735-745.	1.9	44
328	Diet therapy for inflammatory bowel diseases: The established and the new. World Journal of Gastroenterology, 2016, 22, 2179-2194.	1.4	123
329	Bifidobacteria and Their Role as Members of the Human Gut Microbiota. Frontiers in Microbiology, 2016, 7, 925.	1.5	627
330	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. International Journal of Molecular Sciences, 2016, 17, 578.	1.8	55
331	Whole-cell detection of live lactobacillus acidophilus on aptamer-decorated porous silicon biosensors. Analyst, The, 2016, 141, 5432-5440.	1.7	66
332	The role of dietary supplements in inflammatory bowel disease: a systematic review. European Journal of Gastroenterology and Hepatology, 2016, 28, 1357-1364.	0.8	49
333	Novel perspectives on therapeutic modulation of the gut microbiota. Therapeutic Advances in Gastroenterology, 2016, 9, 580-593.	1.4	63
334	Nutraceuticals in Gastrointestinal Disorders. , 2016, , 109-122.		3
335	Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India. Journal of Gastroenterology, 2016, 51, 660-671.	2.3	40
336	Mechanisms and therapeutic effectiveness of lactobacilli. Journal of Clinical Pathology, 2016, 69, 187-203.	1.0	195
337	Probiotics and prebiotics in ulcerative colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 55-71.	1.0	92
338	Multistrain Probiotics. , 2016, , 279-302.		2
339	Probiotics in Inflammatory Bowel Diseases and Cancer Prevention. , 2016, , 755-771.		4
340	Metabolic role of lactobacilli in weight modification in humans and animals. Microbial Pathogenesis, 2017, 106, 182-194.	1.3	85
341	Probiotics, Prebiotics, and Antibiotics in IBD. , 2017, , 455-469.		1
342	Influence of diet on the gut microbiome and implications for human health. Journal of Translational Medicine, 2017, 15, 73.	1.8	1,714

#	Article	IF	Citations
343	Protective effect of Averrhoa bilimbi L. fruit extract on ulcerative colitis in wistar rats via regulation of inflammatory mediators and cytokines. Biomedicine and Pharmacotherapy, 2017, 91, 1113-1121.	2.5	33
344	The role of gut microbiota in health and disease: InÂvitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe, 2017, 44, 3-12.	1.0	130
345	Antibiotics and specialized metabolites from the human microbiota. Natural Product Reports, 2017, 34, 1302-1331.	5.2	58
346	The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis. Journal of Histochemistry and Cytochemistry, 2017, 65, 445-461.	1.3	19
347	Streptococcus thermophilus: From yogurt starter to a new promising probiotic candidate?. Journal of Functional Foods, 2017, 37, 74-89.	1.6	88
348	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clinical Microbiology Reviews, 2017, 30, 191-231.	5.7	67
349	Effect of a probiotic Lactobacillus plantarum TN8 strain on trinitrobenzene sulphonic acidâ€induced colitis in rats. Journal of Animal Physiology and Animal Nutrition, 2017, 101, 311-319.	1.0	5
350	Emerging Trends in â€œSmart Probioticsâ€• Functional Consideration for the Development of Novel Health and Industrial Applications. Frontiers in Microbiology, 2017, 8, 1889.	1.5	134
351	Methanobrevibacter attenuation via probiotic intervention reduces flatulence in adult human: A non-randomised paired-design clinical trial of efficacy. PLoS ONE, 2017, 12, e0184547.	1.1	20
352	Beneficial Influences of Lactobacillus plantarum on Human Health and Disease. , 2017, , 109-117.		7
353	Treatment of Inflammatory Bowel Disease in Ulcerative Colitis. , 2017, , 343-354.		2
354	Lipoteichoic acids are embedded in cell walls during logarithmic phase, but exposed on membrane vesicles in Lactobacillus gasseri JCM 1131^T. Beneficial Microbes, 2018, 9, 653-662.	1.0	16
355	Inflammatory Diseases of the Gut. Journal of Medicinal Food, 2018, 21, 113-126.	0.8	20
357	Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe, 2018, 49, 103-111.	1.0	14
358	Cafeteria diet and probiotic therapy: cross talk among memory, neuroplasticity, serotonin receptors and gut microbiota in the rat. Molecular Psychiatry, 2018, 23, 351-361.	4.1	84
359	Review article: the gut microbiome in inflammatory bowel diseaseâ€”avenues for microbial management. Alimentary Pharmacology and Therapeutics, 2018, 47, 26-42.	1.9	147
361	Translational Development of Microbiomeâ€Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates. Clinical and Translational Science, 2018, 11, 200-207.	1.5	24
362	Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases. Nutrients, 2018, 10, 1723.	1.7	71

#	Article	IF	Citations
363	Benefits of multistrain bacteria formulations for health. Journal of Functional Foods, 2018, 47, 531-546.	1.6	6
364	Rebuilding the Gut Microbiota Ecosystem. International Journal of Environmental Research and Public Health, 2018, 15, 1679.	1.2	231
365	Using bioreactors to study the effects of drugs on the human microbiota. Methods, 2018, 149, 31-41.	1.9	34
366	Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens, 2019, 8, 126.	1.2	464
367	<i>Lactobacillus curvatus</i> CP2998 Prevents Dexamethasone-Induced Muscle Atrophy in C2C12 Myotubes. Journal of Nutritional Science and Vitaminology, 2019, 65, 455-458.	0.2	10
368	Probiotic Lactobacillus and Bifidobacterium strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining. EPMA Journal, 2019, 10, 337-350.	3.3	41
369	The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis. Nutrients, 2019, 11, 293.	1.7	86
370	Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways. MBio, 2019, 10, .	1.8	141
371	Short-Term Probiotic Administration Increases Fecal-Anti Candida Activity in Healthy Subjects. Microorganisms, 2019, 7, 162.	1.6	6
372	Bifidobacterium longumSuppresses Murine Colorectal Cancer through the Modulation of oncomiRs and Tumor Suppressor miRNAs. Nutrition and Cancer, 2019, 71, 688-700.	0.9	45
373	Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity. Autoimmunity Reviews, 2019, 18, 455-475.	2.5	37
374	Mulberry juice freeze-dried powder attenuates the disease severity by the maintaining of colon mucosa in mice with DSS-induced acute colitis. Bioscience, Biotechnology and Biochemistry, 2019, 83, 914-922.	0.6	10
375	Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology. Future Oncology, 2019, 15, 3861-3876.	1.1	13
376	The Microbiome in Patients With Inflammatory Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 243-255.	2.4	38
377	Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy. Cells, 2020, 9, 2283.	1.8	37
378	Microbiota Changes Due to Grape Seed Extract Diet Improved Intestinal Homeostasis and Decreased Fatness in Parental Broiler Hens. Microorganisms, 2020, 8, 1141.	1.6	8
379	Streptococcus thermophilus: To Survive, or Not to Survive the Gastrointestinal Tract, That Is the Question!. Nutrients, 2020, 12, 2175.	1.7	45
380	Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD. Journal of Crohn's and Colitis, 2021, 15, 1222-1235.	0.6	40

#	Article	IF	Citations
381	Probiotics for maintenance of remission in ulcerative colitis. The Cochrane Library, 2020, 3, CD007443.	1.5	71
382	Disease managing capacities and mechanisms of host effects of lactic acid bacteria. Critical Reviews in Food Science and Nutrition, 2021, 61, 1365-1393.	5.4	25
383	Not All Fibers Are Born Equal; Variable Response to Dietary Fiber Subtypes in IBD. Frontiers in Pediatrics, 2020, 8, 620189.	0.9	51
384	Animal Models for Probiotic Interventions Under Gut Inflammatory Conditions. , 2021, , 85-121.		2
385	The metabolic profile of Bifidobacterium dentium reflects its status as a human gut commensal. BMC Microbiology, 2021, 21, 154.	1.3	13
386	Mucositis reduction with probiotics in children with cancer: a randomised-controlled feasibility study. Archives of Disease in Childhood, 2022, 107, 259-264.	1.0	0
387	Longitudinal Survey of Fecal Microbiota in Healthy Dogs Administered a Commercial Probiotic. Frontiers in Veterinary Science, 2021, 8, 664318.	0.9	4
388	High-throughput virtual screening and microsecond MD simulations to identify potential sugar mimic of the solute-binding protein BlAXBP of the ABC transporter from Bifidobacterium animalis subsp. Lactis. Computational Biology and Chemistry, 2021, 93, 107541.	1.1	0
389	Multi-walled carbon nanotubes enhance the genetic transformation of Bifidobacterium longum. Carbon, 2021, 184, 902-909.	5.4	3
390	Probiotics: A Mainstream Therapy for the Disease Suppression. , 2022, , 257-257.		1
391	Designing Probiotics and Its Clinical Applications. , 2021, , 231-251.		2
393	Nutraceuticals in gastrointestinal disorders. , 2021, , 141-155.		2
394	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. , 2011, , 123-150.		2
395	Probiotika bei chronisch entzÃ¼ndlichen Darmerkrankungen. , 2003, , 51-62.		2
396	Probiotics in Clinical Practice as Therapeutics Against Enteric Disorders. , 2011, , 355-373.		1
397	The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Scientific Reports, 2020, 10, 2723.	1.6	14
398	Genes, bacteria and inflammatory bowel disease. Colorectal Disease, 2001, 3, 2-6.	0.7	2
399	Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. Journal of Medical Microbiology, 2016, 65, 201-210.	0.7	46

#	Article	IF	Citations
400	Synbiotics in Human Medicine. , 0, , 307-321.		5
401	Beneficial Effect of Probiotics Administration in Inflammatory Bowel Disease and Related Spondyloarthropathy: A Prospective Study. Medical Science Technology, 0, 56, 100-103.	0.0	3
402	Microbial Factors in the Pathogenesis of IBD. Bioscience and Microflora, 2003, 22, 5-14.	0.5	8
403	Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World Journal of Clinical Cases, 2020, 8, 1361-1384.	0.3	69
404	Effects of Administration of Live or Inactivated Virulent Rhodococccus equi and Age on the Fecal Microbiome of Neonatal Foals. PLoS ONE, 2013, 8, e66640.	1.1	21
405	Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner. PLoS ONE, 2015, 10, e0134050.	1.1	140
406	The effect of probiotics on Ä±ntestinal motility in an experimental short bowel model. Acta Cirurgica Brasileira, 2020, 35, e202000804.	0.3	3
407	Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?. Current Clinical Pharmacology, 2020, 15, 216-233.	0.2	20
408	Mechanisms Involved in the Anti-Inflammatory Properties of Native and Genetically Engineered Lactic Acid Bacteria. Anti-Infective Agents, 2012, 11, 59-69.	0.1	6
409	Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World Journal of Gastroenterology, 2005, 11, 5185-92.	1.4	107
410	Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats. World Journal of Gastroenterology, 2005, 11, 908.	1.4	40
411	Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World Journal of Gastroenterology, 2006, 12, 4452.	1.4	39
412	Current medical therapy of inflammatory bowel disease. World Journal of Gastroenterology, 2000, 6, 483-489.	1.4	16
413	Chapter 2: The composition and role of the microbiota in chickens. , 2015, , 21-50.		3
414	Phenylketonuria: a review of current and future treatments. Translational Pediatrics, 2015, 4, 304-17.	0.5	109
415	The Role of Pre- and Probiotics in the Treatment of Inflammatory Bowel Disease. Journal of Microbial & Biochemical Technology, 2011, s1, .	0.2	1
416	Recent advances in the management of distal ulcerative colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2010, 1, 43.	0.6	28
417	Randomized, Blinded, Placebo-Controlled Trial of De Simone Formulation Probiotic During HIV-Associated Suboptimal CD4+ T Cell Recovery. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 199-207.	0.9	3

#	Article	IF	Citations
419	Use of Prebiotics, Probiotics and Synbiotics in Clinical Immunonutrition. Preventive Nutrition and Food Science, 2002, 7, 332-345.	0.7	1
420	Use of probiotics in inflammatory bowel disease. Nihon Daicho Komonbyo Gakkai Zasshi, 2003, 56, 849-854.	0.1	0
421	Probiotics in inflammatory bowel disease. , 2004, , 708-725.		0
422	An Update on Probiotic Bifidobacteria. , 2004, , .		3
423	Pre-, Pro-, and Synbiotics in Clinical Enteral Nutrition. , 2005, , 265-275.		0
424	Probiotics in the Management of Inflammatory Bowel Diseases?. American Journal of Gastroenterology, 2007, 102, 22-28.	0.2	0
425	Complementary Medicine & Mucosal Immunology -Recent Topics around Inflammatory Bowel Disease. Japanese Journal of Complementary and Alternative Medicine, 2008, 5, 85-101.	1.0	0
428	Probiotics in Ulcerative Colitis. , 2009, , 181-194.		0
429	Probiotics and prebiotics in the management of ulcerative colitis. Food Science and Technology Bulletin, 2009, 5, 93-102.	0.5	0
430	Application of Functional Dairy Products from IBS to IBD. , 2009, , 375-393.		0
431	Probiotics and Inflammatory Immune Responses. , 2010, , 591-610.		0
432	Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease. , 2012, , 517-534.		1
433	The Role of Diet, Prebiotic and Probiotic in the Development and Management of Inflammatory Bowel Diseases (IBD). , 0, , .		0
434	Prospective Uses of Genetically Engineered Lactic Acid Bacteria for the Prevention of Inflammatory Bowel Diseases. , 0, , .		0
435	Probiotics for Autoimmune Diseases: Is There a Benefit?. , 0, , .		0
437	Erkrankungen der Gastrointestinalorgane â^— â^—Ãœberarbeitet und aktualisiert von Dr. Walter Burghardt. , 2014, , 151-270.		0
438	Review of the Evidence for the Use of Probiotics in Gastrointestinal Disorders. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, .	0.2	0
439	Potentials of Probiotics as Alternative Therapy in Combating Bacterial Diseases: A Review. British Journal of Applied Science & Technology, 2014, 4, 1392-1410.	0.2	0

#	Article	IF	Citations
440	Microbial Succession and Gut Health: Probiotics. , 0, , 63-79.		0
443	Pulsatilla chinensis Saponins Ameliorate Inflammation and DSS-Induced Ulcerative Colitis in Rats by Regulating the Composition and Diversity of Intestinal Flora. Frontiers in Cellular and Infection Microbiology, 2021, 11, 728929.	1.8	47
448	Probiotics and inflammatory bowel disease. Journal of the Royal Society of Medicine, 2003, 96, 167-71.	1.1	23
449	Probiotics and medical nutrition therapy. Nutrition in Clinical Care: an Official Publication of Tufts University, 2004, 7, 56-68.	0.2	61
450	Probiotics in the management of inflammatory bowel disease. MedGenMed: Medscape General Medicine, 2005, 7, 19.	0.2	2
451	The emerging therapeutic role of probiotics in inflammatory bowel disease. Gastroenterology and Hepatology, 2008, 4, 634-40.	0.2	3
452	Shaping the (auto)immune response in the gut: the role of intestinal immune regulation in the prevention of type 1 diabetes. American Journal of Clinical and Experimental Immunology, 2013, 2, 156-71.	0.2	24
453	Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial. Journal of Research in Medical Sciences, 2014, 19, 827-33.	0.4	30
454	PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE. International Journal of Probiotics and Prebiotics, 2016, 11, 99-116.	0.5	4
455	Engineered : A promising agent against diseases (Review). Experimental and Therapeutic Medicine, 2020, 20, 285.	0.8	4
456	Effect of intestinal microbiome, antibiotics, and probiotics in the prevention and management of ulcerative colitis. , 2022, , 59-92.		1
457	Engineered Akkermansia muciniphila: A promising agent against diseases (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	18
458	White biotechnology and the production of bio-products. Systems Microbiology and Biomanufacturing, 2022, 2, 413-429.	1.5	9
459	The microbial ecology ofEscherichia coliin the vertebrate gut. FEMS Microbiology Reviews, 2022, 46, .	3.9	34
461	The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Frontiers in Medicine, 2021, 8, 766126.	1.2	11
463	Nutritional and metabolic issues in inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 569-76.	1.3	5
464	Designer Probiotics in Metabolic Disorders. , 2022, , 241-260.		2
465	Relationship between probiotics and living beings for sustainable life on land. , 2022, , 69-84.		0

#	Article	IF	Citations
468	Probiotics as Efficacious Therapeutic Option for Treating Gut-Related Diseases: Molecular and Immunobiological Perspectives. , 2022, , 69-93.		5
469	ILâ€22 and Lactobacillus delbrueckii mitigate alcoholâ€induced exacerbation of DSSâ€induced colitis. Journal of Leukocyte Biology, 0, , .	1.5	1
470	Plasma Microbiome in COVID-19 Subjects: An Indicator of Gut Barrier Defects and Dysbiosis. International Journal of Molecular Sciences, 2022, 23, 9141.	1.8	30
471	Mechanisms and applications of probiotics in healthcare industry. , 2022, , 225-257.		5
472	Colon Targeted Delivery of Mesalamine and Bifidobacterium Bifidum Loaded Hydrogel Beads for the Management of Ulcerative Colitis. SSRN Electronic Journal, 0, , .	0.4	0
473	Probiotics in Processed Dairy Products and Their Role in Gut Microbiota Health. , 0, , .		1
474	Diversity of the gut, vaginal and oral microbiome among pregnant women in South Africa with and without pre-eclampsia. Frontiers in Global Women S Health, 0, 3, .	1.1	2
477	Strain-specific alterations in gut microbiome and host immune responses elicited by tolerogenic Bifidobacterium pseudolongum. Scientific Reports, 2023, 13, .	1.6	8
478	Foodborne Carbon Dot Exposure Induces Insulin Resistance through Gut Microbiota Dysbiosis and Damaged Intestinal Mucus Layer. ACS Nano, 2023, 17, 6081-6094.	7.3	10
484	Herbal Medicines for the Management of Irritable Bowel Syndrome and Constipation Problem. , 2023, , 313-342.		0